Immatics (IMTX) Times Interest Earned (2019 - 2026)
Immatics (IMTX) posted Times Interest Earned of -$0.01 for Q4 2025, down 100.01% sequentially from $176.34 in Q3 2025, and up 99.99% YoY from -$0.01 in Q4 2024.
Powered by 
Analysis
Immatics (IMTX) Times Interest Earned (2019 - 2026) Analysis & Trends
Immatics has reported Times Interest Earned for 7 years, with the latest figure at -$0.01 in Q4 2025.
- Quarterly Times Interest Earned rose 99.99% year-over-year to -$0.01 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.28 (down 488.26% YoY) and the FY2025 annual result came in at -$4.96, down 116.98% from the prior year.
- Times Interest Earned retreated to -$0.01 in Q4 2025 per IMTX's latest filing, from $176.34 in the prior quarter.
- Over five years, Times Interest Earned peaked at $176.34 in Q3 2025 and troughed at -$185.51 in Q4 2024.
- A 5-year average of $10.25 and a median of $3.8 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned sank 7031.94% in 2024, then soared 14756.71% in 2025.
- Over 5 years, Times Interest Earned stood at $52.49 in 2021, then sank by 94.96% to $2.65 in 2022, then sank by 198.33% to -$2.6 in 2023, then tumbled by 7031.94% to -$185.51 in 2024, then soared by 99.99% to -$0.01 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$0.01, $176.34, and -$2.13 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 184.63 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 184.63 |
| Mar 31, 2026 | 148.13 |
| Dec 31, 2025 | 75.50 |
| Sep 30, 2025 | 189.04 |
| Jun 30, 2025 | 2.33 |
| Mar 31, 2025 | 2.65 |
| Dec 31, 2024 | 0.22 |
| Sep 30, 2024 | -0.04 |
| Jun 30, 2024 | 87.10 |
| Mar 31, 2024 | 19.90 |
| Dec 31, 2023 | 9.58 |
| Sep 30, 2023 | 21.12 |
| Jun 30, 2023 | 12.51 |
| Mar 31, 2023 | 7.53 |
| Dec 31, 2022 | -0.01 |
| Sep 30, 2022 | 51.47 |
| Jun 30, 2022 | 40.93 |
| Mar 31, 2022 | -61.32 |
| Dec 31, 2021 | 49.26 |
| Sep 30, 2021 | 134.51 |